KIT and acute myeloid leukemia: Luteolin did not reduce Nrf2 expression considerably but independently reduced cell viability of FLT3-ITD mutated (Molm13, Molm-14, and MV4-11), and c-kit mutated (Kasumi-1) AML cell lines by ~50%.